Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Barbosa

Showing results (441-450 of 465) with videos related to

Pageof 47
Sort By:
Vaccine|June 21, 2022
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritisThays Zanon Casagrande, Ismael Artur da Costa-Rocha, Maria Bernadete Renoldi de Oliveira Gavi, et al.
Human Vaccines & Immunotherapeutics|July 4, 2024
Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndromeKetty Lysie Libardi Lira Machado, Ismael Artur da Costa-Rocha, Laura Gonçalves Rodrigues Aguiar, et al.
Frontiers in Immunology|July 12, 2019
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever VaccineIsmael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, et al.
Frontiers in Immunology|November 8, 2019
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever VaccineIsmael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, et al.
Viruses|July 29, 2023
Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical TrialsMariana Pierre de Barros Gomes, José Henrique Rezende Linhares, Tiago Pereira Dos Santos, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 11, 2025
IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya feverCaio Wilker Teixeira, Jonai Pacheco Dias, Lizandra Morgado-Santos, et al.
Viruses|September 23, 2022
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular InvestigationTamiris Azamor, Ingrid Siciliano Horbach, Danielle Brito E Cunha, et al.
BMC Infectious Diseases|July 16, 2014
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timelineAna Carolina Campi-Azevedo, Paula de Almeida Estevam, Jordana Grazziela Coelho-Dos-Reis, et al.
Frontiers in Immunology|October 17, 2019
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in ChildrenAna Carolina Campi-Azevedo, Laise Rodrigues Reis, Vanessa Peruhype-Magalhães, et al.
Journal of Medical Primatology|November 21, 2020
Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.)André Tavares da Silva Fernandes, Silvia Bahadian Moreira, Luciane Pinto Gaspar, et al.
Pageof 47

Showing results (441-450 of 465) with videos related to

Sort By:
Pageof 47
Vaccine|June 21, 2022
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritisThays Zanon Casagrande, Ismael Artur da Costa-Rocha, Maria Bernadete Renoldi de Oliveira Gavi, et al.
Human Vaccines & Immunotherapeutics|July 4, 2024
Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndromeKetty Lysie Libardi Lira Machado, Ismael Artur da Costa-Rocha, Laura Gonçalves Rodrigues Aguiar, et al.
Frontiers in Immunology|July 12, 2019
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever VaccineIsmael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, et al.
Frontiers in Immunology|November 8, 2019
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever VaccineIsmael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, et al.
Viruses|July 29, 2023
Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical TrialsMariana Pierre de Barros Gomes, José Henrique Rezende Linhares, Tiago Pereira Dos Santos, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 11, 2025
IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya feverCaio Wilker Teixeira, Jonai Pacheco Dias, Lizandra Morgado-Santos, et al.
Viruses|September 23, 2022
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular InvestigationTamiris Azamor, Ingrid Siciliano Horbach, Danielle Brito E Cunha, et al.
BMC Infectious Diseases|July 16, 2014
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timelineAna Carolina Campi-Azevedo, Paula de Almeida Estevam, Jordana Grazziela Coelho-Dos-Reis, et al.
Frontiers in Immunology|October 17, 2019
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in ChildrenAna Carolina Campi-Azevedo, Laise Rodrigues Reis, Vanessa Peruhype-Magalhães, et al.
Journal of Medical Primatology|November 21, 2020
Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.)André Tavares da Silva Fernandes, Silvia Bahadian Moreira, Luciane Pinto Gaspar, et al.
Pageof 47